Literature DB >> 17481850

Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity.

S B Hassan1, C Haglund, A Aleskog, R Larsson, E Lindhagen.   

Abstract

Several in vitro methods have been suggested to predict drug-induced haematotoxicity and species differences; the most commonly used being the clonogenic CFU-GM assay. The aim of the current study was to evaluate whether primary lymphocytes from peripheral blood, assayed with a short-term non-clonogenic assay, could be used to detect species differences in drug sensitivity, and offer an alternative to the CFU-GM assay. The effect of 17 different cytotoxic drugs on lymphocytes from human, dog, rat and mouse was evaluated. A higher sensitivity of human than mouse lymphocytes was seen for topotecan and for 3 of 5 antimetabolites tested. Clear species specificity was also seen for the proteasome inhibitor bortezomib where rodent cells were 50-300 times less sensitive than human cells. Good agreement between our data and published CFU-GM data was observed, suggesting that primary lymphocytes may be a useful model for species difference screening in drug development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17481850     DOI: 10.1016/j.tiv.2007.03.009

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  5 in total

Review 1.  Controlling mass transport in microfluidic devices.

Authors:  Jason S Kuo; Daniel T Chiu
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2011       Impact factor: 10.745

2.  Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Authors:  Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-06       Impact factor: 3.333

3.  Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

Authors:  Jeannine S McCune; Donald E Mager; Meagan J Bemer; Brenda M Sandmaier; Barry E Storer; Shelly Heimfeld
Journal:  Cancer Chemother Pharmacol       Date:  2015-05-17       Impact factor: 3.333

4.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

5.  Beyond AOPs: A Mechanistic Evaluation of NAMs in DART Testing.

Authors:  Ramya Rajagopal; Maria T Baltazar; Paul L Carmichael; Matthew P Dent; Julia Head; Hequn Li; Iris Muller; Joe Reynolds; Kritika Sadh; Wendy Simpson; Sandrine Spriggs; Andrew White; Predrag Kukic
Journal:  Front Toxicol       Date:  2022-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.